According to FutureWise analysis, the market for cell and gene therapy manufacturing services in 2023 is US$6 billion, and is expected to reach US$22.14 billion by 2031 at a CAGR of 17.70%.

The global market for Cell and Gene Therapy Manufacturing Services was valued at approximately $5.9 billion in 2023 and is projected to experience a substantial growth rate of around 18.9% annually from 2024 to 2032. This growth is primarily driven by the increasing demand for innovative treatments targeting rare and chronic diseases, along with heightened investments in drug research and development. Additionally, the expanding capabilities of contract development and manufacturing organizations (CDMOs) play a crucial role in this growth trajectory. Technological advancements in the production of viral vectors, cell processing, and quality assurance are further contributing to market expansion. Furthermore, supportive regulatory frameworks and the introduction of more cell and gene therapies into the market are enhancing the industry's overall outlook, indicating a promising future for this sector.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cell and Gene Therapy Manufacturing Services Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=12112&type=requestsample

Cell and Gene Therapy Manufacturing Services Market Segmentation:

By Type

• Cell Therapy
• Allogeneic
• Mesenchymal Stem Cells
• T-cells
• Induced Pluripotent Stem Cells
• Natural Killer Cells
• Hematopoietic Stem Cells
• Other Allogeneic Cells
• Autologous
• T-cells
• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Natural Killer Cells
• Viral Vector
• Retroviral Vectors
• Adeno-associated Virus Vectors
• Other Viral Vectors
• Gene Therapy
• Non-viral Vector
• Oligonucleotides
• Other Non-viral Vectors
• Viral Vector
• Retroviral Vectors
• Adeno-associated Virus Vectors
• Other Viral Vectors

By Indication

• Oncology Diseases
• Cardiovascular Diseases
• Orthopedic Diseases
• Ophthalmology Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Other Indications

By Application

• Clinical Manufacturing
• Commercial Manufacturing

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Other End Users

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Cell and Gene Therapy Manufacturing Services Market:

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Charles River Laboratories
• Lonza
• Catalent, Inc.
• WuXi AppTec
• Takara Bio Inc
• Nikon Corporation
• Fujifilm Holdings Corporation
• F. Hoffmann-La Roche Ltd.
• Oxford Biomedica plc
• Cell and Gene Therapy Catapult
• The Discovery Labs LLC
• RoslinCT
• Jrs Pharma
• FinVector
• ABL, Inc.
• Resilience
• BioCentriq
• Porton Biopharma Limited
• Andelyn Biosciences
• Commercializing Living Therapies
• Vibalogics
• Anemocyte Srl
• ElevateBio

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=12112&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Cell and Gene Therapy Manufacturing Services Market By Type, By Indication, By Application, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com